Buprenorphine 8 mg

1 INDICATIONS AND USAGE Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine sublingual tablets contain buprenorphine, a partial opioid agonist, and are indicated for the treatment of opioid dependence and is preferred for induction. ( 1 ) Buprenorphine sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

Actavis Pharma, Inc.

FDA Reported Adverse Reactions
`[1] fatigue` `[2] nausea` `[3] drug ineffective` `[4] dyspnoea` `[5] pain` `[6] diarrhoea` `[7] headache` `[8] off label use` `[9] dizziness` `[10] vomiting`

5 years ago

OVAL ORANGE logo 153

16 HOW SUPPLIED / STORAGE AND HANDLING

BUPRENORPHINE sublingual tablets are available as follows: 2 mg – orange, oval tablets debossed with on one side and 156 on the other side. Tablets are supplied in bottles of 30 (NDC 0228-3156-03). 8 mg – orange, oval tablets debossed with on one side and 153 on the other side. Tablets are supplied in bottles of 30 (NDC 0228-3153-03). Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in USP. Store

BUPRENORPHINE sublingual tablets securely and dispose of properly [see Patient Counseling Information ( 17 )] . tablets debossed tablets debossed

More pills like OVAL logo 153